Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against infection challenge .
AuthorsMurphy, Christopher K
O'Donnell, Michelle M
Hegarty, James W
Clostridioides difficile challenge model
Single-strain live biotherapeutic product
MetadataShow full item record
JournalWorld journal of gastrointestinal pathophysiology
PubMed Central IDPMC10505952
AbstractThe Centers for Disease Control and Prevention estimate that Clostridioides difficile (C. difficile) causes half a million infections (CDI) annually and is a major cause of total infectious disease death in the United States, causing inflammation of the colon and potentially deadly diarrhea. We recently reported the isolation of ADS024, a Bacillus velezensis (B. velezensis) strain, which demonstrated direct in vitro bactericidal activity against C. difficile, with minimal collateral impact on other members of the gut microbiota. In this study, we hypothesized that in vitro activities of ADS024 will translate in vivo to protect against CDI challenge in mouse models.